Neurologic Disorders

Role of Medical Cannabinoids Investigated for Children

October 23, 2017

"Additional research is needed to evaluate the potential role of medical cannabinoids in children and adolescents, especially given increasing accessibility from state legalization," write the authors.

First-in-Class Alzheimer's Drug Gets Fast-Tracked by FDA

By October 16, 2017

CT1812 is a first-in-class, orally-administered small molecule that targets the sigma-2 receptor complex on neuronal synapses, displacing beta amyloid oligomers from their binding sites on brain cells and clearing them in to the cerebrospinal fluid.

Dementia Management

October 16, 2017

Dementia care practice recommendations for assisted living residences and nursing homes chart.

Better Risk Factor Modification Strategies Needed for Optimal Stroke Prevention

October 12, 2017

Increases in prevalence of hypertension, diabetes, dyslipidemia, smoking, and drug abuse in AIS

Novel Vagus Nerve Stimulation Device Approved for Drug-Resistant Epilepsy

By October 10, 2017

The system includes a detect-and-respond mode, which is designed to prevent seizures before they start and deliver therapy to stop them if they do.

FDA Approves New Dosage Strength for Ingrezza

By October 05, 2017

The 80mg capsule is expected to be available in 30-count bottles within the next two weeks.

MS-Related Fatigue Reduced With Transcranial Direct Current Stimulation

By October 04, 2017

Fatigue was assessed using the Patient-Reported Outcomes Measurement Information System.

Mylan Gets Approval for Generic Versions of Two Copaxone Strengths

By October 04, 2017

The mechanism by which glatiramer acetate exerts its therapeutic effect in MS is unknown, however it is thought to act by modifying immune processes that are believed to be responsible for the pathogenesis of MS.

Botox Treatment Efficacy Examined for Facial Synkinesis

September 28, 2017

The researchers conducted a prospective cohort study involving 23 patients who underwent treatment for facial synkinesis with botulinum toxin over multiple treatment cycles

No Significant Improvement with Intepirdine in Alzheimer's Disease Study

By September 26, 2017

The study included patients with mild to moderate Alzheimer's disease on donepezil therapy (n= 1315) and compared once-daily oral doses of intepirdine 35mg to placebo over 24 weeks.

Suicidal Ingestion Outcomes Compared Between Bupropion and TCAs

By September 26, 2017

Results showed that bupropion users were more likely to have a seizure, have accompanied tachycardia on presentation, and be admitted to the hospital, compared to those who ingested a TCA.

Unique Oscillatory Dynamics of Bicycling Examined in Parkinson's

September 25, 2017

"Abnormal ~18 Hz oscillations are implicated in the pathophysiology of freezing of gait, and suppressing them may form a key strategy in developing potential therapies," the authors write.

Movement Disorder Symptoms Found to Diminish with Alcohol Intake

September 22, 2017

The researchers found that patients showed a significantly reduced number of conditioned eyeblink responses before alcohol administration versus controls.

Vit D Deficiency: A Risk Factor for MS?

By September 21, 2017

Data showed that a 50nmol/L increase in 25(OH)D correlated with a 39% decreased risk of MS. Specifically, a 43% increased risk of MS was seen in women with 25(OH)D levels <30nmol/L vs. women with levels ≥50nmol/L.

Adverse Effects Compared for Multiple Parkinson's Disease Drugs

September 21, 2017

The researchers found that, compared with placebo, the incidence of adverse reactions of ropinirole, rotigotine, entacapone, and sumanirole were higher in terms of nausea.

Mineral Level May Impact Dementia Risk

September 21, 2017

Researchers found an increased risk of dementia associated with both low serum magnesium levels (≤0.79 mmol/L) and high serum magnesium levels (≥0.90 mmol/L).

New Nymalize Ready-to-Use Dosing Option Available

By September 20, 2017

This new option is intended for patients who need a dosage lower than the standard 20mL (60mg) dose.

Orphan Drug Designation Granted to ALS Treatment

By September 19, 2017

A Phase 2 randomized, double-blind, placebo-controlled trial of AMX0035 titled CENTAUR (nct03127514) has begun with 132 ALS participants enrolled.

Briviact Approved as Monotherapy for Partial-Onset Seizures

By September 15, 2017

The sNDA submitted to support the monotherapy indication included clinical data involving over 2,400 adults with partial-onset seizures.

Aptiom Gains Expanded Pediatric Seizure Indication

By September 14, 2017

The efficacy and safety of Aptiom as monotherapy and adjunct therapy for adults with POS was previously established in 5 multicenter, randomized, controlled studies. This data also supported the safety and tolerability of Aptiom for the treatment of pediatric patients with POS.

Multiple Sclerosis Treatment Highlights

By September 13, 2017

MPR interviewed Dr. John Stoffel to discuss the strategies for diagnosis and management of urinary retention in MS patients, as well as his recommendations for optimal care for these patients.

Do Antiepileptic Treatments Affect Fetal Growth, Preterm Delivery?

September 11, 2017

Increased risk for women on AEDs for epilepsy or other indications; risk varies with drug used.

Anti-PD-1 Therapy Tied to Neurological Adverse Events

September 11, 2017

The researchers found that 2.9% of the 347 patients treated with anti-PD-1 monoclonal antibodies developed subacute onset of neurological complications.

Link Between Cardiovascular Med Use and Cognitive Impairment Explored

September 01, 2017

No link for impaired cognition, antihypertensive, antithrombotic, lipid-modifying agent use

Austedo Approved for the Treatment of Tardive Dyskinesia

By August 31, 2017

Austedo, a vesicular monoamine transporter 2 (VMAT2) inhibitor, was initially approved to treat Huntington's chorea in April 2017.

Epstein-Barr Virus May Increase Risk for Multiple Sclerosis

August 31, 2017

The researchers found that those with MS in all three racial groups were more likely to show signs of infection with EBV.

FDA Reveals Stem Cell Policy Plans Amid Clinic Crackdowns

By August 28, 2017

An FDA inspection of the clinic found that adipose tissue was being processed into stromal vascular fraction (stem cells derived from body fat) which was then administered intravenously or directly into the spinal cord of patients.

Gocovri Approved to Treat Dyskinesia in Patients with Parkinson's Disease

By August 28, 2017

The safety and efficacy of Gocovri was seen in two Phase 3 controlled trials in Parkinson's disease patients with dyskinesia.

High Systolic BP Linked to Negative Cognitive Outcomes

August 23, 2017

Researchers find that healthy reductions may benefit blacks even more than whites

Does Adding Evolocumab to Statin Tx Impact Cognitive Function?

August 17, 2017

The researchers found that the mean change from baseline over time in the raw score for the spatial working memory strategy index of executive function was −0.21 ± 2.62 and −0.29 ± 2.81 in the evolocumab and placebo groups, respectively.